Shared Decision-Making and Risk Stratification in EGFR-Mutant NSCLC

Dr. Julia Rotow emphasizes shared decision-making as essential for frontline treatment selection, noting the dramatic shift from osimertinib monotherapy as standard to combination therapy as default over the past 2 to 3 years. Treatment decisions require balancing disease-associated risk factors with patient-specific considerations.

Disease risk assessment focuses on CNS involvement, TP53 mutations, and overall disease burden. Even "lower-risk" EGFR-mutant lung cancer represents high-risk disease requiring consideration of intensive strategies from diagnosis. Patient factors include overall health, medical comorbidities, social environment affecting treatment feasibility, and personal risk tolerance for aggressive therapy.

Dr. Rotow particularly addresses patient education regarding combination therapy fears. Many patients associate "chemotherapy" with outdated popular culture representations, requiring comprehensive discussions about modern supportive care advances and toxicity mitigation strategies. For patients with high-risk features like CNS involvement or heavy symptomatic disease burden, strong recommendations for combination therapy are appropriate.

The conversation highlights balancing aggressive treatment recommendations with patient autonomy. Some medically eligible patients may hesitate due to toxicity concerns, necessitating detailed discussions about real-world treatment experiences versus perceived risks.

Dr. Ross Camidge introduces practical flexibility in treatment initiation, noting that although clinical trials administered everything on day one, clinicians can start osimertinib monotherapy to establish patient comfort before introducing chemotherapy intensification weeks later.